Plasma levels of thrombin activatable fibrinolysis inhibitor in normal and preeclamptic pregnant women.
To explain the pathogenesis of preeclampsia with coagulation induction or a defective fibrinolysis, various hemostatic parameters were studied and different treatment modalities targeting these parameters were evaluated. Considering the role of TAFI in down-regulation of fibrinolysis, in our study we have investigated whether TAFI contributes to impaired fibrinolysis in patient with preeclampsia. Thirty patients with preeclampsia (mean age +/- SD 25.7 +/- 4.53; range 17-36) and 30 normal pregnant women as control group (mean age +/- SD 28 +/- 5.26; range 21-38) were included in our study. TAFI antigen was determined using an ELISA kit for quantitative measurement. The mean TAFI antigen levels were 12.55 +/- 1.88 microg/ml in patients with preeclampsia and 12.29 +/- 3.0 microg/ml in normal pregnant women. A statistically significant difference was not found between TAFI antigen levels of two groups (p > 0.05). In order to clarify the role of TAFI in the pathogenesis of preeclampsia, in addition to plasma TAFI levels, its synthesis, activation and metabolism should also be evaluated.
Alacacioğlu
Inci
I
Division of Hematology, Institute of Oncology, Dokuz Eylul University, 35340 Izmir, Turkey.
Ozcan
Mehmet Ali
MA
Alacacioğlu
Ahmet
A
Polat
Mesut
M
Yüksel
Faize
F
Demirkan
Fatih
F
Pişkin
Ozden
O
Ozgenç
Yiğit
Y
Ozsan
Hayri Güner
HG
Undar
Bulent
B
D000328:Adult; D015415:Biomarkers / Q000097:blood; D025901:Carboxypeptidase B2 / Q000097:blood*; D005260:Female; D006801:Humans; D011225:Pre-Eclampsia / Q000097:blood* / Q000175:diagnosis*; D011247:Pregnancy / Q000097:blood*; D018570:Risk Assessment / Q000379:methods*; D012307:Risk Factors
D015415:Biomarkers; D025901:Carboxypeptidase B2